Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9P2Q2
UPID:
FRM4A_HUMAN
Alternative names:
-
Alternative UPACC:
Q9P2Q2; A7E2Y3; Q5T377
Background:
FERM domain-containing protein 4A plays a crucial role in regulating epithelial cell polarity, connecting ARF6 activation with the PAR3 complex. It shares a redundant role with FRMD4B in epithelial polarization and may influence MAPT secretion through ARF6-signaling pathways.
Therapeutic significance:
Linked to Agenesis of the corpus callosum, with facial anomalies and cerebellar ataxia, understanding the role of FERM domain-containing protein 4A could open doors to potential therapeutic strategies.